The Latest Breaking News from Zimmer Biomet Holdings

As pickleball injuries rise, this medical device stock is perfectly positioned to cash in on the sport’s booming popularity.

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

  Zimmer Biomet Holdings (NYSE:ZBH) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

Friday marks the last chance for investors to receive the next dividend payout from Zimmer Biomet Holdings (NYSE:ZBH).

Analysts have provided the following ratings for Zimmer Biomet Holdings (NYSE:ZBH) within the last quarter:

Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings within the last quarter:

The shares of healthcare products and solutions provider Zimmer Biomet (ZBH) plunged in price after the company posted a dismal fourth-quarter earnings report. The company cited pandemic-induced challenges as having hampered its performance, while also anticipating these challenges will persist this year. So, will ZBH’s stock be able to gain…

Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings within the last quarter: